Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 2 Interventional Results available

Carboplatin +/- Nivolumab in Metastatic Triple Negative Breast Cancer

ClinicalTrials.gov ID: NCT03414684

Open the official record

This page only displays public information reproduced from the official ClinicalTrials.gov record NCT03414684. It adds no medical advice, opinions, or eligibility judgments. The official record remains the source of truth for eligibility criteria, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Nov 18, 2026, 6:57 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Randomized Phase II Trial of Carboplatin With or Without Nivolumab in First-line Metastatic Triple-negative Breast Cancer

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

This research study is studying a drug called Carboplatin with or without another study drug, Nivolumab as a possible treatment for triple-negative breast cancer that has spread to other parts of the body. The interventions involved in this study are: * Carboplatin * Nivolumab

Study identification

NCT ID
NCT03414684
Recruitment status
Completed
Study type
Interventional
Phase
Phase 2
Enrollment
78 participants

Conditions and interventions

Conditions

Interventions

Drug

Eligibility (public fields only)

Age range
18 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Jan 30, 2018 (Actual)
Primary completion
Sep 28, 2021 (Actual)
Completion
Aug 5, 2026 (Actual)
Last update posted
Sep 9, 2026

2018 – 2026

United States locations

U.S. sites
10
U.S. states
6
U.S. cities
8
Facility City State ZIP Site status
The Stamford Hospital Stamford Connecticut 06904 —
Eastern Maine Medical Center Bangor Maine 04401 —
Beth Israel Deaconess Medical Center Boston Massachusetts 02115 —
Dana-Farber Cancer Institute Boston Massachusetts 02115 —
St. Elizabeth's Medical Center Boston Massachusetts 02135 —
Dana-Farber/Brigham and Women's Cancer Center at Milford Regional Medical Center Milford Massachusetts 01757 —
Dana-Farber/Brigham and Women's Cancer Center in clinical affiliation with South Shore Hospital South Weymouth Massachusetts 02190 —
Dana-Farber/New Hampshire Oncology-Hematology Londonderry New Hampshire 03053 —
Ohio State University Columbus Ohio 43210 —
University of Vermont Medical Center Burlington Vermont 05401 —

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT03414684, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Sep 9, 2026 · Synced Nov 18, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.